Different Doses of vPDT in the Treatment of cCSC

Brief Title

Different Doses of vPDT in the Treatment of cCSC

Official Title

Comparison of Different Doses of Verteporfin Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy

Brief Summary

      This is a prospective, randomized and controlled clinical trial of photodynamic therapy (PDT)
      for chronic central serous chorioretinopathy (CSC). The patients who met the inclusion
      criteria were randomly divided into 50% dose PDT treatment group and 70% dose PDT treatment
      group. The primary treatment success rate and adverse event rate of the two groups were
      compared by optical coherence tomography (OCT), and then the best PDT treatment scheme for
      chronic CSC was summarized.
    

Study Type

Interventional

Primary Outcome

The complete absorption rate of subretinal fluid

Secondary Outcome

 Central foveal thickness change after the PDT

Condition

Central Serous Chorioretinopathy

Intervention

50% dose of photodynamic therapy

Study Arms / Comparison Groups

 50% dose of PDT

Description:  Patients received 50% dose of verteporfin PDT therapy.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Status

Procedure

Estimated Enrollment

100

Start Date

January 1, 2020

Completion Date

December 31, 2023

Primary Completion Date

December 31, 2022

Eligibility Criteria

        Inclusion Criteria:

          -  18-75 years old, regardless of gender;

          -  Meet the diagnostic criteria of central serous chorioretinopathy;

          -  The course of CSC (subject to the symptoms of this disease) is more than 3 months;

          -  Patients with simultaneous diseases of both eyes were included in those with more
             subretinal fluid.

        Exclusion Criteria:

          -  macular neuroretinal detachment caused by rhegmatogenous retinal detachment, uveitis,
             age-related macular degeneration, polypoid choroidal angiopathy and other fundus
             diseases;

          -  a previous history of PDT treatment;

          -  systemic hormone or local hormone nasal spray is being used, or hormone is stopped for
             less than 3 months.
      

Gender

All

Ages

18 Years - 75 Years

Accepts Healthy Volunteers

No

Contacts

Yuou Yao, Dr, 13651177854, [email protected]

Location Countries

China

Location Countries

China

NCT ID

NCT05390619

Organization ID

RDL2020-04

Responsible Party

Principal Investigator

Study Sponsor

Peking University People's Hospital

Study Sponsor

Yuou Yao, Dr, Study Chair, Peking University People's Hospital

Verification Date

May 2022